Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 1.00 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29677084 | 1.00 | PTPN11 (1.00) | PTPN11MAPK3MAPK1 | |
| SCHEMBL16925048 | 1.00 | PTPN11 (1.00) | PTPN11MAPK3MAPK1 | |
| SCHEMBL16925047 | 1.00 | PTPN11 (1.00) | PTPN11MAPK3MAPK1 | |
| SCHEMBL31184222 | 0.94 | PTPN11 (0.88) | PTPN11MAPK3MAPK1 | |
| SCHEMBL16914211 | 0.94 | PTPN11 (0.88) | PTPN11MAPK3MAPK1 | |
| SCHEMBL20032855 | 0.90 | PTPN11 (0.82) | PTPN11 | |
| SCHEMBL20032884 | 0.90 | PTPN11 (0.82) | PTPN11 | |
| SCHEMBL20382829 | 0.89 | PTPN11 (0.81) | PTPN11 | |
| SCHEMBL20032861 | 0.89 | PTPN11 (0.81) | PTPN11 | |
| SCHEMBL16925211 | 0.88 | PTPN11 (1.00) | PTPN11MAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110730678-B | Pharmaceutical combination comprising an ALK inhibitor and an SHP2 inhibitor | 诺华股份有限公司 | 2022-07-15 | — | — | CN | claimed |
| US-12053470-B2 | Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor | NOVARTIS AG (CH) | 2024-08-06 | — | — | US | disclosed |
| US-20220241277-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN ALK INHIBITOR AND A SHP2 INHIBITOR | NOVARTIS AG (CH) | 2022-08-04 | — | — | US | disclosed |
| CN-110730678-B | Pharmaceutical combination comprising an ALK inhibitor and an SHP2 inhibitor | 诺华股份有限公司 | 2022-07-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12053470-B2 | Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor | ALK, PTPRJ, PTPN1 | PTPN11 10/4885MAPK3 406/4885MAPK1 367/4885 |
| US-20220241277-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN ALK INHIBITOR AND A SHP2 INHIBITOR | ALK, PTPRJ, PTPN1 | PTPN11 10/4885MAPK3 406/4885MAPK1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.